These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34001398)

  • 1. Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals.
    Almeida LR; Criado RF; Criado PR; Ensina LF; Abdalla BMZ; Quaresma JAS
    An Bras Dermatol; 2021; 96(4):497-499. PubMed ID: 34001398
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab for the treatment of chronic inducible urticaria in 80 patients.
    Exposito-Serrano V; Curto-Barredo L; Aguilera Peiro P; Gómez Armayones S; Serra-Baldrich E; Spertino J; Bonfill Ortí M; Figueras Nart I; Melé-Ninot G; Baliu-Piqué C; Sala Cunill A; Labrador-Horrillo M; Guilabert Vidal A; Fernández Chico N; Giménez-Arnau AM
    Br J Dermatol; 2021 Jan; 184(1):167-168. PubMed ID: 32730636
    [No Abstract]   [Full Text] [Related]  

  • 3. Real world evidence on treatment of chronic spontaneous urticaria with omalizumab: Preliminary data.
    Corrao S; Prestigiacomo MA; Angileri RG; Natoli G; Argano C
    Dermatol Ther; 2020 Jul; 33(4):e13458. PubMed ID: 32319167
    [No Abstract]   [Full Text] [Related]  

  • 4. Omalizumab in chronic inducible urticaria: A retrospective, real-life study.
    Fialek M; Dezoteux F; Le Moing A; Karimova E; Ramdane N; Pape E; Azib-Meftah S; Staumont-Sallé D
    Ann Dermatol Venereol; 2021 Dec; 148(4):262-265. PubMed ID: 34247853
    [No Abstract]   [Full Text] [Related]  

  • 5. "Omalizumab plus": Combining omalizumab with immunosuppression for treatment of refractory chronic urticaria: A multicenter UK series.
    Rutkowski K; Wagner A; Jui-Lin Choo K; Smith H; Savic S; Grattan CE
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1400-1401.e2. PubMed ID: 33181342
    [No Abstract]   [Full Text] [Related]  

  • 6. Effective omalizumab interval prolongation in the treatment of chronic urticaria.
    Alizadeh Aghdam M; Pieterse RH; Kentie PA; Rijken F; Knulst AC; Röckmann H
    J Allergy Clin Immunol Pract; 2020; 8(10):3667-3668.e1. PubMed ID: 32679351
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose omalizumab use in patients with chronic spontaneous urticaria.
    Alizadeh Aghdam M; van den Broek F; Rijken F; Knulst AC; Röckmann H
    J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1426-1427.e1. PubMed ID: 31678293
    [No Abstract]   [Full Text] [Related]  

  • 8. Pityriasis rosea during omalizumab treatment for chronic spontaneous urticaria.
    Vaccaro M; Marafioti I; Cannavò SP; Ciccarese G; Drago F
    Dermatol Ther; 2020 Nov; 33(6):e14356. PubMed ID: 33009684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria.
    Castagna J; Bernard L; Hacard F; Delcroix F; Darrigade AS; Nicolas JF; Decullier E; Nosbaum A; Bérard F
    Br J Dermatol; 2020 Dec; 183(6):1124-1126. PubMed ID: 32531805
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic spontaneous urticaria refractory to cyclosporine add-on omalizumab successfully treated with methotrexate add-on.
    Garbayo-Salmons P; Expósito-Serrano V
    Dermatol Ther; 2020 Nov; 33(6):e14469. PubMed ID: 33112010
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine and omalizumab together: A new option for chronic refractory urticaria.
    Sánchez J; Alvarez L; Cardona R
    J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2101-2103. PubMed ID: 32112923
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria.
    Buters TP; van der Velden WAC; Abdisalaam I; van Maaren MS; van Doorn MBA
    J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3227-3229. PubMed ID: 33915307
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.
    Passante M; Napolitano M; Dastoli S; Bennardo L; Fabbrocini G; Nisticò SP; Patruno C
    Dermatol Ther; 2021 Nov; 34(6):e15111. PubMed ID: 34427028
    [No Abstract]   [Full Text] [Related]  

  • 14. Omalizumab in children and adolescents with chronic urticaria: A 16-week real-world study.
    Song XT; Chen YD; Yu M; Liu B; Zhao ZT; Maurer M
    Allergy; 2021 Apr; 76(4):1271-1273. PubMed ID: 33275779
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term follow-up effect of omalizumab in chronic spontaneous urticaria and its association with serum C-reactive protein levels.
    Baysak S; Sevim Kecici A; Dogan B
    Dermatol Ther; 2020 Jul; 33(4):e13663. PubMed ID: 32447802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria.
    Murray C; Ridge K; Conlon N
    Eur J Dermatol; 2023 Oct; 33(5):561-562. PubMed ID: 38297938
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness of Omalizumab in Patients with Chronic Inducible Urticaria: real-life experience from two UCARE centres.
    Can PK; Salman A; Hoşgören-Tekin S; Kocatürk E
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e679-e682. PubMed ID: 34013560
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of Omalizumab on Anaphylaxis in Patients Treated for Chronic Urticaria.
    Song X; Liu B; Yu M; Liao S; Luan T; Li C; Zhao Z
    Int Arch Allergy Immunol; 2023; 184(2):199-201. PubMed ID: 36327946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria.
    Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
    Allergy; 2021 Apr; 76(4):1274-1277. PubMed ID: 33314187
    [No Abstract]   [Full Text] [Related]  

  • 20. Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study.
    Di Bona D; Nettis E; Bilancia M; Ridolo E; Minenna E; Nizi MC; Albanesi M; Caiaffa MF; Macchia L
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2482-2485.e2. PubMed ID: 33677081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.